Are surrogate end points in drug-eluting stent trials reliable?
نویسندگان
چکیده
5-lipoxygenase gene disruption reduces amyloidpathology in a mouse model of Alzheimer’s disease. FASEB J 2008;22:1169 –78. 6. Manev R, Imbesi M, Uz T, Dzitoyeva S, Dimitrijevic N, Manev H. Effects of 5-lipoxygenase inhibitors MK-886 and caffeic acid in a model of forced swimming in wild-type and 5-lipoxygenase– deficient mice. Program 711.4/BB17. 2007 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2007. Available at: http://www. abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey {B531E434-A1EE-476C-9071-52AC68106587}&SKey {531A911D5233-4F6D-99FB-928B3456C2F8}&MKey {FF8B70E5-B7F9-4D07A58A-C1068FDE9D25}&AKey {3A7DC0B9-D787-44AA-BD08FA7BB2FE9004}. Accessed March 27, 2008. 7. Stewart JC, Janicki DL, Muldoon MF, Sutton-Tyrrell K, Kamarck TW. Negative emotions and 3-year progression of subclinical atherosclerosis. Arch Gen Psychiatry 2007;64:225–33.
منابع مشابه
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials.
OBJECTIVES We sought to validate 4 angiographic measures as potential surrogates for clinical restenosis (target lesion revascularization [TLR]) after stent implantation. BACKGROUND Given the low revascularization rates with drug-eluting stents (DES), an angiographic surrogate of TLR is desirable to reduce the sample size required to demonstrate efficacy in future trials of antirestenosis dev...
متن کاملLetter regarding article by Mauri et al, "Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison".
BACKGROUND Published rates of coronary restenosis have fallen below 10% in drug-eluting stent trials. Early evaluations of new stents have used continuous end points that are presumed surrogates for restenosis, but the generalizability and power of such end points have not been examined systematically. METHODS AND RESULTS We examined the relationship between incremental changes in observed la...
متن کاملLate Loss in Lumen Diameter and Binary Restenosis for Drug-Eluting Stent Comparison
Background—Published rates of coronary restenosis have fallen below 10% in drug-eluting stent trials. Early evaluations of new stents have used continuous end points that are presumed surrogates for restenosis, but the generalizability and power of such end points have not been examined systematically. Methods and Results—We examined the relationship between incremental changes in observed late...
متن کاملOverview of Intracoronary Brachytherapy for in-Stent Restenosis of a Drug-Eluting Stent
Percutaneous coronary intervention with stenting is considered recently as the most common procedure for the treatment of symptomatic coronary. The article reviewed 41 studies published during 1997-2019 on intracoronary brachytherapy for in-stent restenosis of a drug-eluting stent. Intracoronary radiation therapy was finally confirmed in the setting of in-stent restenosis using as adjunctive th...
متن کاملClinical End Points in Coronary Stent Trials
Background—Although most clinical trials of coronary stents have measured nominally identical safety and effectiveness end points, differences in definitions and timing of assessment have created confusion in interpretation. Methods and Results—The Academic Research Consortium is an informal collaboration between academic research organizations in the United States and Europe. Two meetings, in ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of the American College of Cardiology
دوره 51 20 شماره
صفحات -
تاریخ انتشار 2008